Heidelberg Pharma AG and Advanced Proteome Therapeutics Corporation announced advances in their collaborative activities. The companies have agreed to test the combination of APC's proprietary site-selective protein modification technology and Heidelberg Pharma's proprietary ATAC technology in order to generate superior cancer therapeutics. Since the inception of the partnership, activities have been centered on antibody-Amanitin conjugates that are produced using controlled conjugation methods and possess high target-specific cytotoxic potency.

The companies have successfully demonstrated the generation of ATACs using APC's proprietary protein modification technology.